Connect with us

Uncategorized

Aleafia Health Announces Appointment of Pharmaceutical Executive Tricia Symmes as Chief Commercial Officer

Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) today announced the appointment of Tricia Symmes as the Company’s Chief Commercial Officer, effective August 27, 2020. Symmes brings over 20 years of experience as a senior executive in the pharmaceutical, consumer packaged goods, and cannabis industries. Reporting to Aleafia Health CEO Geoffrey Benic, […]

The post Aleafia Health Announces Appointment of Pharmaceutical Executive Tricia Symmes as Chief Commercial Officer appeared first on Technical420.

Republished by Plato

Published

on

Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) today announced the appointment of Tricia Symmes as the Company’s Chief Commercial Officer, effective August 27, 2020.

Symmes brings over 20 years of experience as a senior executive in the pharmaceutical, consumer packaged goods, and cannabis industries. Reporting to Aleafia Health CEO Geoffrey Benic, she will lead the development and execution of the Company’s product launches, sales, marketing and corporate development initiatives in the adult-use, medical and international cannabis markets.

“Tricia’s leadership experience comes up at an exciting juncture for Aleafia Health as we strengthen and expand our adult-use and medical portfolios with new, differentiated health and wellness products,” said Benic. “Tricia’s proven track record and leadership in bringing best-in-class pharmaceutical, over-the-counter and innovative cannabis products to market will bring value to our patients, customers and shareholders as we enter a new and exciting phase in Aleafia Health’s development.”

“With a dynamic, industry-leading production ecosystem in place, this is an incredibly exciting time to join Aleafia Health. As we execute our Cannabis 2.0 strategy, the Company is poised to succeed with high-quality, innovative products at scale,” said Symmes. “Our team looks forward to expanding Aleafia Health’s product portfolio and establishing meaningful market share and brand recognition on both a national and global level as we open new market channels.”

Most recently, Ms. Symmes served as General Manager at CX Industries, a wholly owned subsidiary of WeedMD Inc. Ms. Symmes has extensive executive C-suite experience in the pharmaceutical, biotech and cannabis industries in both North American and international markets. Serving as chief operating officer and general manager of multinational public companies, including Alcon Canada and Novartis Pharmaceuticals, she has extensive CPG experience and is well-versed in consumer trends having led the development and execution of commercialization strategies, operations, business development, sales, and marketing. She holds an MBA from Charles Sturt University (Australia), and an Honours BSc in Kinesiology (Western University).

Following a transition period, Chief Marketing & Technology Officer Trevor Newell departs the Company effective August 28, 2020.

For Investor and Media Relations, please contact:

Nicholas Bergamini, VP Investor Relations
1-833-TSX-ALEF (879-2533)
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a leading, vertically integrated cannabis health and wellness company with four primary business units: Cannabis Cultivation & Products, Health & Wellness Clinics, Cannabis Education, and Consumer Experience with ecommerce, retail distribution and provincial supply agreements.

Aleafia Health owns three major cannabis product & cultivation facilities, two of which are licensed and operational including the first large-scale, operational outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and has international operations in three continents.

Innovation is at the heart of Aleafia Health competitive advantage. The Company maintains a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value and has been named the 2019 top performing company of the year by the TSX Venture Exchange prior to graduation to the TSX.

Forward Looking Information 

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Primary Logo Source: https://technical420.com/cannabis-article/aleafia-health-announces-appointment-of-pharmaceutical-executive-tricia-symmes-as-chief-commercial-officer/

Uncategorized

Will BevCanna Be Able To Compete Long Term With The Likes Of HEXO Corp. and Canopy Growth?

After staying quiet for several months, BevCanna Enterprises Inc. (BEV.CN) (BVNNF) has been busy and has reported three separate announcements this week. One of the most important developments to be reported by BevCanna was the completion of trial production runs of its exclusively licensed line of Keef Beverages as well as the white-label beverages it […]

The post Will BevCanna Be Able To Compete Long Term With The Likes Of HEXO Corp. and Canopy Growth? appeared first on Technical420.

Republished by Plato

Published

on

After staying quiet for several months, BevCanna Enterprises Inc. (BEV.CN) (BVNNF) has been busy and has reported three separate announcements this week.

One of the most important developments to be reported by BevCanna was the completion of trial production runs of its exclusively licensed line of Keef Beverages as well as the white-label beverages it is producing for State B Beverages.

BevCanna produced and evaluated multiple formulations (i.e. sparkling water, tea-based and soda formats) and multiple bottling formats. The company conducted tests on shelf stability and we are favorable on the thoroughness of the pre-production process. BevCanna plans to start product commercialization by the first quarter of 2021, assuming that it is granted the necessary processing licenses.

Another key development is related to strengthening BevCanna’s balance sheet. The Canadian cannabis beverage company recently received a $750,000 capital injection from a private placement as well as $500,000 from the exercising of 1.5 million stock options by the senior management team.

The other announcement from BevCanna was related to the addition of retail beverage marketer Donald Wood to the company’s independent advisory board. The company expects him to bring a wealth of sales and marketing experience in the beverage sector to the business and we will monitor the impact that he has on the operation.

Currently, BevCanna is trading at $0.27 and we are favorable on the management teams’ decision to exercise the stock options. We are of the opinion that this shows that the management team has confidence in the operation and considers it to be undervalued.

The funds are being used to prepare BevCanna’s industry-leading high-capacity beverage manufacturing facility for the granting of a standard processing license from Health Canada. Prior to the financing announcement, BevCanna was trending higher and was building momentum. We believe that BevCanna is an opportunity to be aware of following the recent developments and will keep an eye on how the story evolves from here.

If you are interested in learning more about BevCanna Enterprises, please send an email to support@technical420.com with the subject ‘BevCanna Enterprises’ to be added to our distribution list.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/will-bevcanna-be-able-to-compete-long-term-with-the-likes-of-hexo-corp-and-canopy-growth/

Continue Reading

CBD

Hemptown USA Has Built A World Class Platform To Capitalize On The Booming Hemp Industry

In early 2021, we expect Hemptown USA to complete a go-public transaction and this is an opportunity that our readers should be aware of. We have been covering Hemptown since 2018 and are impressed with how the story has evolved during this time. In early 2017, Hemptown started to cultivate feminized hemp and is considered […]

The post Hemptown USA Has Built A World Class Platform To Capitalize On The Booming Hemp Industry appeared first on Technical420.

Republished by Plato

Published

on

In early 2021, we expect Hemptown USA to complete a go-public transaction and this is an opportunity that our readers should be aware of. We have been covering Hemptown since 2018 and are impressed with how the story has evolved during this time.

In early 2017, Hemptown started to cultivate feminized hemp and is considered to be a leading player in the cannabigerol (CBG) market. When we first met with Hemptown’s management team, the company was one of the few businesses to be focused on CBG and we are favorable on this focus.

Hemptown’s management team has a proven track record of success and is comprised of executives that previously worked at Fortune 500 companies (Intel and Kelloggs). We are favorable on how the management team has been able to make Hemptown standout in what has become a saturated market.

Positioned to Capitalize on the Current Market Environment

One of the reasons we are favorable on the opportunity is related to the infrastructure that has been put in place. Currently, Hemptown’s state-of-the-art FDA registered and cGMP certified facility is operating at 30% capacity and we expect this percentage to increase in 2021. Many of the company’s competitors are running out of capital and we have seen several CBD and CBG companies file for bankruptcy.

Last year, Hemptown raised $24 million through a series of private placements and has been cutting costs to conserve capital. This has left the business in a strong position to execute and we expect the company to record strong revenue growth as it ramps up capacity.

Another reason we are excited about Hemptown is related to how the business has evolved. The company has launched a line of hemp cigarettes that do not contain any nicotine and are made with CBD and CBG that is from its Oregon farm.

We have considered the hemp cigarette vertical to be an attractive market and are favorable on how Hemptown has differentiated its product line from what is currently available on the market. The products include a proprietary terpene infused filter that is available in a variety of flavors and we are favorable on this aspect of the story.

In a report from Cowen and Company, the US hemp industry is expected to be a $16 billion market by 2025. The passing of the 2018 US Farm Bill was a major catalyst for the cannabinoid market as it opened the door for an era of CBD commoditization. Following the passing of the bill, major retailers like Walgreens and CVS have entered the industry.

The surge of interest in the CBD market led to an even larger increase in the amount of production that companies had in place. This put substantial pressure on the price of CBD and high-profile operators like GenCanna (backed by Mitch McConnell) were forced to file for bankruptcy.

By being focused on multiple cannabinoids and by conserving cash, Hemptown has been able to survive the current market environment. We expect this aspect of the story to play an important role in how the business continues to grow and believe that Hemptown  is an operator to be aware of.

We believe that the next phase of growth for the market will be related to a surge in interest in cannabinoids like CBG, cannabichromene (CBC) and cannabidivarin (CBDV). We believe that Hemptown is positioned to be a beneficiary of this growth and will monitor how the story continues to evolve.

Executing on a Multi-Faceted Growth Strategy

Last year, Hemptown acquired Kirkman which is an established brand that has been in business for more than 70 years. Kirkman operates out of a facility that is FDA licensed and cGMP certified. When the acquisition was reported, we became increasingly excited about the opportunity and believe that Kirkland has played a key role how Hemptown has launched products.

By using state-of-the-art equipment for precision dosing, Hemptown has been able to create a diverse product line that includes tinctures, capsules, creams, topicals, gums, and edibles. The focus on being vertically integrated could increase margins by up to 20x and we are bullish on the impact that the facility has had on the economics of the business.

On top of selling its own product line, Hemptown offers white label products and we are favorable on the structure of the business. These products use premium cannabinoids and are fully traceable from seed-to-bottle. Hemptown’s white label platform is a full service offering that includes branding, fulfillment, and marketing services.

By operating a business model that has diversified revenue streams, Hemtown has been able to protect itself from decreasing CBD prices. The business model is based on margins and this is a key metric to be focused on. The strategy allows Hemptown to monetize inventory in multiple channels that are based on the demand and margins.

The saturation of the CBD market has substantially raised the cost of the end-consumer. Hemptown’s ability to sell to businesses and to consumers has protected margins while also being able to scale revenue. We believe that the strategy will allow Hemptown to efficiently monetize inventory and will monitor how the management is able to execute on this.

Focused on the International Opportunity

Another major potential growth driver for Hemptown is the expansion into the European Union (EU). Hemptown is pursuing a FSA license in the United Kingdom for its CBD and CBG products as well as bulk ingredients. The opportunity in the EU is massive and this is a market that we have been bullish on for several years.

Currently, Hemptown is in advanced discussions to partner with an established European supply chain that will provide it with the opportunity to move over 1,000 kilograms of CBD per month. We are favorable on the potential revenue that is associated with the relationship and will monitor how the company is able to capitalize on the EU market.

A Private Opportunity to be Aware of

Hemptown has attractive growth prospects and plans to make additional acquisitions to scale the business. The management has used a series of organic and inorganic growth initiatives to bring the business to where it is today.

We are favorable on the types of acquisitions that Hemptown has made and expect an additional acquisition to immediately prove to be accretive. We have faith in the management team’s ability to identify a business that would be complementary to the existing assets in place and are bullish on the potential impact it would have.

In early 2021, Hemptown plans to go public and this is an opportunity that we are closely following. If you are interested in learning more about Hemptown, please send an email to support@technical420.com with the subject “Hemptown” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/hemptown-usa-has-built-a-world-class-platform-to-capitalize-on-the-booming-hemp-industry/

Continue Reading

Uncategorized

Aurora Cannabis Obtains Receipt for Final Base Shelf Prospectus Reiterates Fiscal Q1 Guidance

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has filed and been receipted on a final short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada , except […]

The post Aurora Cannabis Obtains Receipt for Final Base Shelf Prospectus Reiterates Fiscal Q1 Guidance appeared first on Technical420.

Republished by Plato

Published

on

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has filed and been receipted on a final short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada , except Quebec , and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).

Aurora Cannabis Inc. Logo (CNW Group/Aurora Cannabis Inc.)

The filing of the shelf prospectus is expected to provide financial flexibility to execute against previously stated business objectives. The Company expects to be in full compliance with all financial covenants as at September 30, 2020 under our amended and restated credit facility. Aurora’s relationship with the lending syndicate remains strong and there are no new obligations to repay any portion of the credit facility until its stated maturity date.

Following the divestiture of non-core subsidiaries during fiscal 2020, net revenue for the three months ended September 30, 2020 are expected to be comprised almost entirely of cannabis net revenue and expected to be at the high end of our previously announced $60 million to $64 million range, compared to $67.5 millionin Q4 2020. The Company also expects adjusted gross margin before fair value adjustments on cannabis net revenue to be at the high end of our previously announced 46%-50% range.

SG&A costs (including R&D) for the three months ended September 30, 2020 are expected to be in the low $40 million range after excluding certain one-time contract and employee termination costs.  Aurora continues to expect to achieve positive adjusted EBITDA in the second quarter of fiscal 2021.

About Aurora

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta , Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website atwww.auroramj.com .

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.

Forward Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (” forward-looking statements “). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include statements regarding: the Company’s goals of achieving positive Adjusted EBITDA and positive free cash flow. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 24, 2020 (the ” AIF “) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.edgar.gov . The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

The Company uses financial measures regarding itself, such as Adjusted EBITDA, that do not have standardized meaning under the International Financial Reporting Standards (” IFRS “) and may not be comparable to similar measures presented by other entities (” non-IFRS measures “). Further information relating to non-IFRS measures, is set out in the Company’s management discussion and analysis for the three and twelve months ended June 30, 2020 and 2019 under the heading “Cautionary Statement Regarding Non-GAAP Performance Measures” and the “Revenue” section for reconciliation to the IFRS equivalent.

Cision

View original content to download multimedia: http://www.prnewswire.com/news-releases/aurora-cannabis-obtains-receipt-for-final-base-shelf-prospectus-reiterates-fiscal-q1-guidance-301163790.html

SOURCE Aurora Cannabis Inc.

Source: https://technical420.com/cannabis-article/aurora-cannabis-obtains-receipt-for-final-base-shelf-prospectus-reiterates-fiscal-q1-guidance/

Continue Reading
CBD4 days ago

The New Italian Cannabis Contradiction

Heartland4 days ago

Bought Haven St. 150 peace tea. Looking for a review before I brew myself a cup

CBD2 days ago

Will Europe THC Limit Increase to 0.3%?

News4 days ago

Sugarbud Announces Supply Agreement with British Columbia Liquor Distribution Branch

Heartland4 days ago

Who Is Newly Lobbying On Cannabis?

Heartland4 days ago

Dosage recommendation and does it make anyone else feel groggy all day?

Heartland4 days ago

Vaping CBD flower doesn’t really do anything. Can you vape hash? Is my flower just too weak?

Heartland4 days ago

CBD vs CBN: What’s The Actual Difference?

Heartland5 days ago

Terp Town

News4 days ago

FluroTech Announces Filing of Patent Applications With Respect to Its Proprietary Diagnostic Test Method and Pandemic Defense Platform

News4 days ago

Rubicon Organics Establishes Route to Market for Cannabis 2.0 Products

Heartland4 days ago

CBD flower and hair testing?

Heartland4 days ago

What cbd cartridge brand is the best?

Heartland4 days ago

CBG for Crohn’s

Heartland3 days ago

Accountants from Coast to Coast Meet to Discuss Cannabis Issues

Heartland5 days ago

Global Cannabidiol Oil (CBD Oil) Market Data Analysis 2020-2026: Whistler, CBD American …

Heartland4 days ago

Canada’s Stubborn Black-Market Cannabis Problem

Heartland4 days ago

Cannabis Tycoon Curaleaf expected to monetize loads after Connecticut Legalizes

News4 days ago

Canada House Wellness Group Enters into Distribution Agreement for Cannabis 2.0 Products

News4 days ago

Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study

Heartland4 days ago

MMJ Recs Medical Marijuana Cards And Your Privacy: Are MMJ Cards Confidential?

Heartland4 days ago

Exclusive: Colorado’s Governor Jared Polis Talks Legal Cannabis

Heartland4 days ago

CBD Hemp Oil Market Research Report Covers – Product Types, Applications, Market Share …

Heartland4 days ago

Is this site legit, or no?

News3 days ago

EBV Elektronik adds NanoXplore to its linecard

Heartland5 days ago

American Shaman Coupon Code 2020

Heartland5 days ago

Global Cannabidiol Oil (CBD Oil) Market Data Analysis 2020-2026: Whistler, CBD American …

Heartland5 days ago

Get the calming and pain-relieving benefits of CBD with these gummies

Heartland4 days ago

Three more Ag Things to Know

Material4 days ago

Kinetic investigation of self-reduction basic oxygen furnace dust briquettes using charcoals from different biomass

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America